Member Info for PM2022

A CEO that tries hard and does what she says she will. Great recent effort by Suzy. Lots of interviews and updates coming through. Now we just need some institutional investors in early 2022.

Hopefully rise to the 40s-50s before the deal is announced. SIgnificant upside here.

All building up to the official announcement. Only a few days left. Don't forget we added another drug into the pipeline. What a pipeline we have for only 19 million and a deal worth 100s million inclusive of royalties.

Brilliant update. No delay expected. 19 million market cap. Huge rerate coming.

I don't do names and it does not matter. If someone immediately sold after the last RNS which was positive and at this price then i can only see one reason why and that would be down to costs therefore you can work out who it might be. People will always sell. We just need new investors.

So why did the price crash from 65p to 30p giving us a market cap of only 20 million? I know one from that list that has sold all his shares if not most.

What Val needs is volume and new investors. People will always come and go as the price goes up so no point forward predicting what others may do.

News on Monday a real possibility and should hit 1p soon. Such a low market cap well worth a buy at these levels.

I will keep adding with every drop.

Great news. A great pipeline of drugs now with a couple of phase 2 drugs all for 20 million. Looks cheap and a deal only days away as well. Great risk to reward here.

Hopefully Cenkos will bring in some buyers once this deal is finalised. We always drop when an important RNS is released. We need a bit of momentum to settle at better market cap and no better time than once the deal is finalised.

We are so cheap so everything to gain and hopefully we get a decent rally for a change and settle at a higher price.

Market cap only 18 million. Huge upside potential and a great entry point if you can hold.

Not if you look at the buys. News is about to arrive so not sure which stock you are following.

Hopefully Cenkos are doing a bit of work to bring in institutional investors and HNWIs. Cenkos are in at 22p so would not want the SP to drop much from here given it is so undervalued anyway.

Val is on the radar for many so could be anyone buying. Bottom line we got transformational news coming and it is very likely institutional investors will come soon as well in the next few weeks. Anything below 70-80p is cheap at the moment with huge upside potential even at that price provided the deal is completed as expected so not surprised with a tiny increase in SP.

Great presentation and strategy. No other AIM stock like this.

1) From what we know already that institutional investors are being target to buy into our stock without a dilution. Only 65 million shares.
2) Deal due for Val 201 by the end of the year worth a few hundred million including royalties.
3) Likely new drug to be into the pipeline in the new few weeks with roughly about 4 to be added into the pipeline a year. Great new projects from universities which not many companies are doing.
4) Currently in negotiations for VAl 301 and Val 401 to be partnered.
5) Cenkos are in at 22p so a great positive to be riding with us.

I expect a significant re-rate at this ridiculous 20 market cap once a deal is finalised in the coming days/weeks. No placing in the near future with significant upside potential. Fantastic risk to reward investment. We should be at least multiples of this in the next few weeks based on peer group comparisons.

Maybe tomorrow. Suzy needs to bring her A game tonight and create a bit of much needed momentum. Current market cap a joke. A signal of some positive imminent news would be good for the market.

I used to hear the lifeboats at 17p from Valtree and we went all the way to 65p. Now this is a positive sign that the lifeboats are coming out again maybe we will hit 80p from here in the coming weeks now that Valtree is back and calling the lifeboats again.

Presentation tomorrow 6pm-8pm and likely many institutional investors will be watching. Deal for 201 should not be far away now plus we should get some news for the Physiomics project soon.

Market cap very cheap and plenty of upside here especially in the next week or two.

Suzy made it very clear no dilution to get in Institutional investors. Only time we could get a dilution will be sometime in the future if it is value adding but I don't that would be for a very long time.

I think it's important to get the word out regarding the presentation next week and post on Twitter, Telegram groups so that we get as much viewers as possible. Ultimately the buys are what will make the SP go to where it should be so we need more publicity and more people watching.

I suspect Cenkos will try and get the entire world into this stock in the coming months given they are in at 22p.

No dilution to get institutional investors in and a deal for 201 to come shortly. Seriously good value at this market cap and only 65 million shares with most tightly held. I can see this be a few pounds this time next year. We should go like SAR did and this would be a fantastic entry point.

Deal only days away as tomorrow is December and during the meeting last month it was stated they have considered the Christmas break and will try and get the deal out in good time.

The presentation next week to the market and institutional investors should give us good publicity followed by strong buying pressure. Few updates due including PYC update and possibly a new drug to be added into the pipeline before Christmas.

Lets get Suzy on Loose Women. I think the story for women's health and the vision here would sell big as it is a niece market as well as the potential treatments for cancer. The more emails the better chance it will get picked up.

By Phone: 0344 88 14150
Loose.Women@itv.com

I think next week will be interesting. I think a large number of institutional investors will be watching the presentation having studied the broker notes on VAL.

We could have some large buys following the presentation followed by a deal, new drug into the pipeline and PYC update by the end of the year. A great entry point at this market cap at this time.